GAËL ROUÉ, PhD
+34 932275400 (ext 4525)
IDIBAPS-CEK Building, 2nd floor
C/ Rosselló 149-153. 08036 Barcelona
My team is dedicated to the characterization of new therapeutic targets in aggressive B-cell lymphoma, including drug-resistant mantle cell lymphoma (MCL) and “double hit” diffuse large B cell lymphoma (DH-DLBCL), which define two sub-groups of lymphoid neoplasm with a really poor prognosis and recurrent refractoriness to standard therapies. Our main research areas include the analysis of therapeutic compounds developed and validated by recognized pharmaceutical companies and academic groups, and the molecular and genetic characterization of the factors that determine the efficacy and safety of each treatment, in a set of more than 60 primary samples and cell lines, and in transgenic, systemic or xenotransplant mouse models of MCL and (DH-)DLBCL. The final objective of our work is the design of individualized therapies, as it is intended that the information obtained can serve for the conduct of phase I/II clinical trials, in partnership with the biotechnology companies and the Hemathology departments associated to our projects.
B-cell lymphoma, proteasome, oncogenes, epigenetic regulators, immunomoduatory drugs, tumor microenvironment, mouse model